These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 35245388)

  • 1. Low incidence of hyperacute graft-versus-host disease (GVHD) with effective GVHD prophylaxis based on anti-thymocyte globulin.
    Radici V; Stocker N; Dulery R; Brissot E; Bannet A; van de Wyngaert Z; Sestili S; Belhocine R; Bonin A; Ledraa T; Mohty M; Malard F
    Br J Haematol; 2022 Jun; 197(5):630-633. PubMed ID: 35245388
    [No Abstract]   [Full Text] [Related]  

  • 2. Addition of anti-thymocyte globulin to standard graft-versus-host disease prophylaxis versus standard treatment alone in patients with haematological malignancies undergoing transplantation from unrelated donors: final analysis of a randomised, open-label, multicentre, phase 3 trial.
    Walker I; Panzarella T; Couban S; Couture F; Devins G; Elemary M; Gallagher G; Kerr H; Kuruvilla J; Lee SJ; Moore J; Nevill T; Popradi G; Roy J; Schultz KR; Szwajcer D; Toze C; Foley R;
    Lancet Haematol; 2020 Feb; 7(2):e100-e111. PubMed ID: 31958417
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Post-transplant cyclophosphamide versus anti-thymocyte globulin as graft- versus-host disease prophylaxis in haploidentical transplant.
    Ruggeri A; Sun Y; Labopin M; Bacigalupo A; Lorentino F; Arcese W; Santarone S; Gülbas Z; Blaise D; Messina G; Ghavamzadeh A; Malard F; Bruno B; Diez-Martin JL; Koc Y; Ciceri F; Mohty M; Nagler A
    Haematologica; 2017 Feb; 102(2):401-410. PubMed ID: 27758821
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low dose anti-thymocyte globulin reduces chronic graft-versus-host disease incidence rates after matched unrelated donor transplantation.
    Tandra A; Covut F; Cooper B; Creger R; Brister L; McQuigg B; Caimi P; Malek E; Tomlinson B; Lazarus HM; Otegbeye F; Kolk M; de Lima M; Metheny L
    Leuk Lymphoma; 2018 Jul; 59(7):1644-1651. PubMed ID: 29199482
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low incidence of severe acute and chronic graft-versus-host disease in a long-term retrospective study with ATG Grafalon routine use.
    Kovacsova F; Folber F; Weinbergerova B; Stepanova R; Kabut T; Tomiska M; Krejci M; Mayer J
    Ann Hematol; 2023 Dec; 102(12):3587-3591. PubMed ID: 37783854
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Does anti-thymocyte globulin have a place in busulfan/fludarabine conditioning for matched related donor hematopoietic stem cell transplantation?
    Ji YS; Lee MS; Min CW; Park SK; Kim SH; Yun J; Kim HJ; Kim KH; Kim CK; Lee KT; Won JH; Hong DS
    Korean J Intern Med; 2016 Jul; 31(4):750-61. PubMed ID: 27017944
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-thymocyte globulin (thymoglobulin), tacrolimus, and sirolimus as acute graft-versus-host disease prophylaxis for unrelated hematopoietic stem cell transplantation.
    Al-Kadhimi Z; Gul Z; Rodriguez R; Chen W; Smith D; Mitchell A; Abidi M; Ayash L; Deol A; Lum L; Forman S; Ratanatharathorn V; Uberti J
    Biol Blood Marrow Transplant; 2012 Nov; 18(11):1734-44. PubMed ID: 22710143
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Defibrotide combined with triple therapy including posttransplant cyclophosphamide, low dose rabbit anti-t-lymphocyte globulin and cyclosporine is effective in prevention of graft versus host disease after allogeneic peripheral blood stem cell transplantation for hematologic malignancies.
    Akpinar S; Kayikci O; Tekgunduz E
    Transfus Apher Sci; 2022 Feb; 61(1):103367. PubMed ID: 35120825
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incidence and risk factor of hemorrhagic cystitis after allogeneic transplantation with fludarabine, busulfan, and anti-thymocyte globulin myeloablative conditioning.
    Lam W; Storek J; Li H; Geddes M; Daly A
    Transpl Infect Dis; 2017 Jun; 19(3):. PubMed ID: 28199755
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Posttransplant Cyclophosphamide and Antithymocyte Globulin versus Posttransplant Cyclophosphamide as Graft-versus-Host Disease Prophylaxis for Peripheral Blood Stem Cell Haploidentical Transplants: Comparison of T Cell and NK Effector Reconstitution.
    Makanga DR; Guillaume T; Willem C; Legrand N; Gagne K; Cesbron A; Gendzekhadze K; Peterlin P; Garnier A; Le Bourgeois A; Béné MC; Chevallier P; Retière C
    J Immunol; 2020 Sep; 205(5):1441-1448. PubMed ID: 32747504
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ATG prevents severe acute graft-versus-host disease in mismatched unrelated donor hematopoietic cell transplantation.
    Pidala J; Tomblyn M; Nishihori T; Ayala E; Field T; Fernandez H; Perez L; Locke F; Alsina M; Ochoa JL; Perkins J; Tate C; Shapiro J; Conwell M; Bookout R; Anasetti C
    Biol Blood Marrow Transplant; 2011 Aug; 17(8):1237-44. PubMed ID: 21215811
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk factors for chronic graft-versus-host disease after anti-thymocyte globulin-based haploidentical hematopoietic stem cell transplantation in acute myeloid leukemia.
    Lv M; Zhang X; Xu L; Wang Y; Yan C; Chen H; Chen Y; Han W; Wang F; Wang J; Liu K; Huang X; Mo X
    Front Med; 2019 Dec; 13(6):667-679. PubMed ID: 31512033
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The impact of graft-versus-host disease prophylaxis in reduced-intensity conditioning allogeneic stem cell transplant in acute myeloid leukemia: a study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
    Rubio MT; Labopin M; Blaise D; Socié G; Contreras RR; Chevallier P; Sanz MA; Vigouroux S; Huynh A; Shimoni A; Bulabois CE; Caminos N; López-Corral L; Nagler A; Mohty M
    Haematologica; 2015 May; 100(5):683-9. PubMed ID: 25769546
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Post-transplant cyclophosphamide combined with anti-thymocyte globulin for graft-vs-host disease prophylaxis improves survival and lowers non-relapse mortality in older patients undergoing allogeneic hematopoietic cell transplantation.
    Pasic I; Lipton JH; Kim DD; Viswabandya A; Kumar R; Lam W; Law AD; Mattsson J; Michelis FV
    Ann Hematol; 2020 Jun; 99(6):1377-1387. PubMed ID: 32382774
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Post-Transplant Cyclophosphamide Combined with Anti-Thymocyte Globulin as Graft-versus-Host Disease Prophylaxis for Allogeneic Hematopoietic Cell Transplantation in High-Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome.
    Alanazi W; Chen S; Lipton JH; Kim DD; Viswabandya A; Kumar R; Lam W; Law AD; Al-Shaibani Z; Mattsson J; Michelis FV
    Acta Haematol; 2021; 144(1):66-73. PubMed ID: 32428903
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-thymocyte globulins for post-transplant graft-versus-host disease prophylaxis-A systematic review and meta-analysis.
    Theurich S; Fischmann H; Chakupurakal G; Shimabukuro-Vornhagen A; Chemnitz JM; Holtick U; Rothe A; Scheid C; Hallek M; Skoetz N; von Bergwelt-Baildon M
    Crit Rev Oncol Hematol; 2013 Oct; 88(1):178-86. PubMed ID: 23561334
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alemtuzumab vs anti-thymocyte globulin in patients transplanted from an unrelated donor after a reduced intensity conditioning.
    Robin M; Raj K; Chevret S; Gauthier J; de Lavallade H; Michonneau D; McLornan D; Peffault de Latour R; Potter V; Kulasekararaj A; Sicre de Fontbrune F; Pagliuca A; Yakoub-Agha I; Socié G; Mufti GJ
    Eur J Haematol; 2018 Oct; 101(4):466-474. PubMed ID: 29714032
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Individualised dosing of anti-thymocyte globulin in paediatric unrelated allogeneic haematopoietic stem-cell transplantation (PARACHUTE): a single-arm, phase 2 clinical trial.
    Admiraal R; Nierkens S; Bierings MB; Bredius RGM; van Vliet I; Jiang Y; Lopez-Yurda M; Versluijs AB; Zwaan CM; Lindemans CA; Boelens JJ
    Lancet Haematol; 2022 Feb; 9(2):e111-e120. PubMed ID: 35114150
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparative study of porcine antihuman lymphocyte globulin versus antithymocyte globulin-fresenius in an allogeneic hematopoietic cell transplantation conditioning regimen for severe aplastic anemia.
    Zhang Y; Liu L; Si Y; Miao M; Qiu H; Tang X; Han Y; Fu C; Jin Z; Chen S; Sun A; Wu D
    Hematology; 2021 Dec; 26(1):741-750. PubMed ID: 34555301
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Role of Low-dose Anti-thymocyte Globulin as Standard Prophylaxis in Mismatched and Matched Unrelated Hematopoietic Peripheral Stem Cell Transplantation for Hematologic Malignancies.
    Sakellari I; Batsis I; Bousiou Z; Mallouri D; Constantinou V; Gavriilaki E; Smias C; Yannaki E; Kaloyannidis P; Papaioannou G; Stavroyianni N; Syrigou A; Sotiropoulos D; Fylaktou A; Tsompanakou A; Saloum R; Anagnostopoulos A
    Clin Lymphoma Myeloma Leuk; 2017 Oct; 17(10):658-666. PubMed ID: 28716402
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.